July 6, 2017
The U.S. Food and Drug Administration (FDA) expanded the approved use of subcutaneous Actemra (tocilizumab) to treat adults with giant cell arteritis. This new indication provides the first FDA-approved therapy, specific to this type of vasculitis.
See more information on this news item.
Giant cell arteritis
If you have problems viewing PDF files, download the latest version of Adobe Reader
For language access assistance, contact the NCATS Public Information Officer
Genetic and Rare Diseases Information Center (GARD) - PO Box 8126, Gaithersburg, MD 20898-8126 - Toll-free: 1-888-205-2311